With Brigham and Women’s Hospital and Boston Children’s Hospital, Dana-Farber has performed thousands of stem cell/bone marrow transplants for adult and pediatric patients with blood cancers and other serious illnesses. What’s the difference between these two terms? As it turns out, the only real distinction is in the method of collecting the stem cells. Let’s start with the basics.
Alyssa Ywuc was a 23-year-old nursing student when she was diagnosed with leukemia. After seeing first-hand the work of oncology nurses as a patient, she decided to specialize in oncology nursing. We talked with Alyssa about both sides of the cancer experience – her time as a patient and her future career as a caregiver.
Aromatase inhibitors (AIs), such as Arimidex, Aromasin, and Femara, have proven to be more effective than previous hormonal treatments for treating both early and advanced breast cancer in post-menopausal women whose tumors are dependent on estrogen. Compared with tamoxifen, these drugs are less likely to cause blood clots or raise the risk of endometrial cancer. As a result, AIs are used both in patients with early breast cancer and in those with metastatic disease.
By Lola Baltzell People often ask me: How do you manage to live with metastatic breast cancer? One of the most important strategies for me has been building a support network. My diagnosis of breast cancer that had already spread to my bones came out of the blue. I had a normal mammogram 13 months earlier, and no known risk factors. So when I heard the news in August 2008, my first impulse was to reach out for support.
In 2012, it is estimated that more than 22,000 new cases of ovarian cancer will be found, and over 15,000 women will die from the disease, according to the National Cancer Institute. Unfortunately, in many cases the cancer isn’t detected until it is advanced. It’s important to recognize the symptoms and urge the women in your life to take early action.
September is Ovarian Cancer Awareness Month and in recognition of that, we asked ovarian cancer survivor Margaret Winchester to share her story. After being diagnosed with advanced (stage IIIC) ovarian cancer in 2008, I chose Dana-Farber for my care because I knew about the Institute’s cutting-edge approach to cancer care and research.